Proliferative Diabetic RetinopathyNCT00596505
Intravitreal Bevacizumab Pretreatment for Reducing Preretinal Hemorrhage in Diabetic Vitrectomy
An observational study of Proliferative Diabetic Retinopathy, run by National Taiwan University Hospital at 1 site in Taiwan.
Trial summary
Treatment of severe proliferative diabetic retinopathy (PDR) may require the use of silicone oil for long-term retinal tamponade to prevent recurrent retinal detachment. Massive bleeding during surgery before proper release of traction and peri-silicone oil proliferation after surgery were major causes of surgical… Read more about this study
- Who is it for?
- Ages 20 to 80 years
- Conditions the study is for
- Proliferative Diabetic Retinopathy
- Type of treatment
- Injection or infusion
- How many people
- 41 participants
- Where
- 1 siteTaiwan
- Study dates
- Apr 2007to Dec 2007
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Consecutive patients undergoing primary pars plana vitrectomy with silicone oil infusion for complications of proliferative diabetic retinopathy will be recruited for the prospective study.
Who may be able to join
- anticoagulant therapy has not been used prior to surgery or during post-operative follow-up period
- no medical history of blood diseases associated with abnormal blood coagulation is present.
Who cannot join
- Not primary pars plana vitrectomy
- post-operative follow-up duration less than three months
Trial locations and contacts
1 site in 1 country.
Taiwan1 site
Department of Ophthalmology, National Taiwan University Hospital
Taipei, 100
About this study
Official title: Intravitreal Bevacizumab (Avastin) Pretreatment for Reducing Intraoperative and Postoperative Preretinal Hemorrhage in Primary Diabetic Vitrectomy With Silicone Oil Infusion
Treatment of severe proliferative diabetic retinopathy (PDR) may require the use of silicone oil for long-term retinal tamponade to prevent recurrent retinal detachment. Massive bleeding during surgery before proper release of traction and peri-silicone oil proliferation after surgery were major causes of surgical failure. The likelihood of reproliferation rises in the presence of significant preretinal blood. It is therefore crucial to reduce intraoperative and postoperative preretinal hemorrhage in complicated diabetic vitrectomy with silicone oil infusion.
Intravitreal avastin has been noted to induce rapid regression of retinal and iris neovascularization in proliferative diabetic retinopathy. Further, presurgical administration of intravitreal avastin may reduce intraoperative bleeding during membrane dissection in PDR with traction retinal detachment. The pretreatment of avastin may be particularly beneficial in the treatment of severe active fibrovascular proliferation by decreasing the severity of intraoperative and postoperative intraocular hemorrhage, leading to better surgical outcome and early visual rehabilitation.
We conduct a prospective study to evaluate the effect of avastin on the severity of intra- and post-operative bleeding, frequency of recurrent bleeding, and anatomical and functional outcome in eyes with severe active PDR undergoing vitrectomy with silicone oil infusion.
Read the detailed description
From January 2007 to June 2007, consecutive patients undergoing primary pars plana vitrectomy with silicone oil infusion for complications of proliferative diabetic retinopathy will be recruited for the prospective study. The selection criteria are: 1) anticoagulant therapy has not been used prior to surgery or during post-operative follow-up period; 2) no medical history of blood diseases associated with abnormal blood coagulation is present. Active PDR is defined as visible large new vessels within the proliferative tissue with fresh preretinal and/or vitreous hemorrhage. Decision of silicone oil infusion will be made before surgery when potential creation of multiple breaks or incomplete traction release is anticipated during surgery due to severe vitreoretinal adhesion. The morphological criteria set for silicone oil infusion are: severe active fibrovascular proliferation with broad vitreous attachment around the disc, arcade and extending to the periphery in at least 2 quadrants (≥grade 5 in Eliott's grading system);8 presence of macular-off traction or combined traction and rhegmatogenous retinal detachment.
Individual recruited patient will be randomly assigned to one of the two groups: group 1 will receive intravitreal injection of 1.25 mg of avastin (0.05 ml) 7 to 9 days before vitrectomy; group 2 will not receive avastin pretreatment. Standard 3 port pars plana vitrectomy will be performed followed by silicone oil (5000 CS) infusion. A total of 30 cases (15 in each group) will be recruited.
After surgery, patients will be kept in a prone position overnight, then allowed to lie on either side during sleep thereafter, but maintained a head-down position during waking hours for 2 weeks. Ophthalmological examinations will be performed in the first 4 days after surgery, then weekly for 4 weeks, biweekly for 1 month, and then monthly for at least 3 months.
The preoperative, intraoperative, and postoperative data will be collected for each patient. These demographics and clinical findings include age, gender, study eye, types and duration of diabetes mellitus, systemic diseases such as hypertension, renal insufficiency (24 hours creatinine clearance estimated by Cockcroft and Gault equation), degree of intraoperative bleeding, duration of the surgery, combined lens extraction, and the use of scleral buckle. Data regarding the extent of preretinal blood in the first postoperative day; time, duration, frequency and treatment of recurrent vitreous hemorrhage; and the duration of postoperative follow-up will also be compiled. Results of ophthalmological examinations, including best corrected visual acuity, intraocular pressure, and lens status will be recorded.
Intraoperative bleeding will be graded in 3 levels: grade 1 is defined as minor bleeding stopped either spontaneously or by transient bottle elevation; grade 2 is defined as moderate bleeding resulting in broad sheaths of clots requiring endodiathermy to the bleeding sites to stop the bleeding; grade 3 is defined as thick clot formation covering half or more of the posterior pole or interfering with the surgical plane. Postoperative preretinal blood will be separated into 3 grades: isolated clots with total area less than 10 disc area and without involvement of the posterior pole (grade1); broad sheaths of clots with total area more than 10 disc area without involving the posterior pole (grade2); broad sheaths of clots with total area more than 10 disc area and with involvement of the posterior pole (grade3). Any noticeable increase of preretinal blood will be defined as recurrent hemorrhage.
The severity of intraoperative bleeding, the extent of immediate postoperative preretinal blood, reabsorption time of blood around the disc area, total reabsorption time of preretinal blood, the rate and treatment of recurrent vitreous hemorrhage, and the change of best-corrected visual acuity will be compared between groups 1 and 2. Visual acuity will be graded into three levels: low (≤1 meter counting fingers), moderate (>1 meter counting fingers, but < 20/200), and good (≥ 20/200).
- Conditions
- Proliferative Diabetic Retinopathy
- Keywords
- proliferative diabetic retinopathy, bevacizumab (Avastin), vitreous hemorrhage, silicone oil
- Medical subject headings
- Vitreous Hemorrhage
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| 1 | Group 1 will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy | |
| 2 | Group 2 will not receive bevacizumab pretreatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
The severity of intraoperative and postoperative preretinal hemorrhage
Measured: Six months
Reabsorption time of blood around the disc area
Measured: Six months
The changes of visual acuity
Measured: Six months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jan 2008 (estimated)
- Study startApr 2007
- Primary completionDec 2007
- Study completionDec 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Proliferative Diabetic RetinopathyStudies of the same condition, open and under way.
- More trials run by National Taiwan University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 41 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital
- Sponsor type
- University, hospital or other
- Investigators
- Chung-May Yang, MD, Principal investigator, National Taiwan University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00596505
- Sponsor's protocol ID
- 200704021M
- Status last verified
- Jan 2008
- First submitted
- 8 Jan 2008
- Last updated
- 17 Jan 2008
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 17 Jan 2008. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Intravitreal Bevacizumab (Avastin) Pretreatment for Reducing Intraoperative and Postoperative Preretinal Hemorrhage in Primary Diabetic Vitrectomy With Silicone Oil Infusion
- ClinicalTrials.gov ID
- NCT00596505
- Acronym / sponsor ID
- 200704021M
- Conditions
- Proliferative Diabetic Retinopathy
- Keywords
- proliferative diabetic retinopathy, bevacizumab (Avastin), vitreous hemorrhage, silicone oil
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 41 participants (actual)
- Lead sponsor
- National Taiwan University HospitalUniversity, hospital or other
- Study start
- Apr 2007
- Primary completion
- Dec 2007 (actual)
- Study completion
- Dec 2007 (actual)
- First posted
- 17 Jan 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Treatment of severe proliferative diabetic retinopathy (PDR) may require the use of silicone oil for long-term retinal tamponade to prevent recurrent retinal detachment. Massive bleeding during surgery before proper release of traction and peri-silicone oil proliferation after surgery were major causes of surgical failure. The likelihood of reproliferation rises in the presence of significant preretinal blood. It is therefore crucial to reduce intraoperative and postoperative preretinal hemorrhage in complicated diabetic vitrectomy with silicone oil infusion.
Intravitreal avastin has been noted to induce rapid regression of retinal and iris neovascularization in proliferative diabetic retinopathy. Further, presurgical administration of intravitreal avastin may reduce intraoperative bleeding during membrane dissection in PDR with traction retinal detachment. The pretreatment of avastin may be particularly beneficial in the treatment of severe active fibrovascular proliferation by decreasing the severity of intraoperative and postoperative intraocular hemorrhage, leading to better surgical outcome and early visual rehabilitation.
We conduct a prospective study to evaluate the effect of avastin on the severity of intra- and post-operative bleeding, frequency of recurrent bleeding, and anatomical and functional outcome in eyes with severe active PDR undergoing vitrectomy with silicone oil infusion.
Detailed description
From January 2007 to June 2007, consecutive patients undergoing primary pars plana vitrectomy with silicone oil infusion for complications of proliferative diabetic retinopathy will be recruited for the prospective study. The selection criteria are: 1) anticoagulant therapy has not been used prior to surgery or during post-operative follow-up period; 2) no medical history of blood diseases associated with abnormal blood coagulation is present. Active PDR is defined as visible large new vessels within the proliferative tissue with fresh preretinal and/or vitreous hemorrhage. Decision of silicone oil infusion will be made before surgery when potential creation of multiple breaks or incomplete traction release is anticipated during surgery due to severe vitreoretinal adhesion. The morphological criteria set for silicone oil infusion are: severe active fibrovascular proliferation with broad vitreous attachment around the disc, arcade and extending to the periphery in at least 2 quadrants (≥grade 5 in Eliott's grading system);8 presence of macular-off traction or combined traction and rhegmatogenous retinal detachment.
Individual recruited patient will be randomly assigned to one of the two groups: group 1 will receive intravitreal injection of 1.25 mg of avastin (0.05 ml) 7 to 9 days before vitrectomy; group 2 will not receive avastin pretreatment. Standard 3 port pars plana vitrectomy will be performed followed by silicone oil (5000 CS) infusion. A total of 30 cases (15 in each group) will be recruited.
After surgery, patients will be kept in a prone position overnight, then allowed to lie on either side during sleep thereafter, but maintained a head-down position during waking hours for 2 weeks. Ophthalmological examinations will be performed in the first 4 days after surgery, then weekly for 4 weeks, biweekly for 1 month, and then monthly for at least 3 months.
The preoperative, intraoperative, and postoperative data will be collected for each patient. These demographics and clinical findings include age, gender, study eye, types and duration of diabetes mellitus, systemic diseases such as hypertension, renal insufficiency (24 hours creatinine clearance estimated by Cockcroft and Gault equation), degree of intraoperative bleeding, duration of the surgery, combined lens extraction, and the use of scleral buckle. Data regarding the extent of preretinal blood in the first postoperative day; time, duration, frequency and treatment of recurrent vitreous hemorrhage; and the duration of postoperative follow-up will also be compiled. Results of ophthalmological examinations, including best corrected visual acuity, intraocular pressure, and lens status will be recorded.
Intraoperative bleeding will be graded in 3 levels: grade 1 is defined as minor bleeding stopped either spontaneously or by transient bottle elevation; grade 2 is defined as moderate bleeding resulting in broad sheaths of clots requiring endodiathermy to the bleeding sites to stop the bleeding; grade 3 is defined as thick clot formation covering half or more of the posterior pole or interfering with the surgical plane. Postoperative preretinal blood will be separated into 3 grades: isolated clots with total area less than 10 disc area and without involvement of the posterior pole (grade1); broad sheaths of clots with total area more than 10 disc area without involving the posterior pole (grade2); broad sheaths of clots with total area more than 10 disc area and with involvement of the posterior pole (grade3). Any noticeable increase of preretinal blood will be defined as recurrent hemorrhage.
The severity of intraoperative bleeding, the extent of immediate postoperative preretinal blood, reabsorption time of blood around the disc area, total reabsorption time of preretinal blood, the rate and treatment of recurrent vitreous hemorrhage, and the change of best-corrected visual acuity will be compared between groups 1 and 2. Visual acuity will be graded into three levels: low (≤1 meter counting fingers), moderate (>1 meter counting fingers, but < 20/200), and good (≥ 20/200).
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 | – | –Group 1 will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy |
| 2 | – | –Group 2 will not receive bevacizumab pretreatment |
Who may qualify
- Ages
- 20 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Consecutive patients undergoing primary pars plana vitrectomy with silicone oil infusion for complications of proliferative diabetic retinopathy will be recruited for the prospective study.
Key inclusion criteria (2 listed)
- anticoagulant therapy has not been used prior to surgery or during post-operative follow-up period
- no medical history of blood diseases associated with abnormal blood coagulation is present.
Key exclusion criteria (2 listed)
- Not primary pars plana vitrectomy
- post-operative follow-up duration less than three months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The severity of intraoperative and postoperative preretinal hemorrhage
Time frame: Six months
Reabsorption time of blood around the disc area
Time frame: Six months
The changes of visual acuity
Time frame: Six months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jan 2008.
Related trials for Proliferative Diabetic Retinopathy
Recruiting
To Investigate the Feasibility and Acceptability of Trained Non-medical Professionals Performing Laser Treatment for Proliferative Diabetic Retinopathy (PDR), and the Potential Impact on Service Capacity. Assess Feasibility of Conducting a Full Trial Comparing Trained ECPs With Ophthalmologists
Proliferative Diabetic Retinopathy (PDR)
RecruitingPhase 2
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
Diabetic Retinopathy
RecruitingObservational study
Longitudinal Observational Study of Diabetic Retinopathy Progression in Type 2 Diabetes Patients
Diabetic Retinopathy, Diabetes Mellitus, Type 2
Not yet recruitingPhase 4
Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.
Proliferative Diabetic Retinopathy, Diabetic Retinopathy
Active, not recruitingPhase 2
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chung-May Yang, MD principal investigator
National Taiwan University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Proliferative Diabetic Retinopathy, run by National Taiwan University Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Jan 2008. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The severity of intraoperative and postoperative preretinal hemorrhage (time frame: Six months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jan 2008.